Alliance Global Partners Estimates Cresco Labs Q3 Earnings

Cresco Labs Inc. (OTCMKTS:CRLBF) – Equities researchers at Alliance Global Partners lifted their Q3 2025 EPS estimates for Cresco Labs in a note issued to investors on Wednesday, March 12th. Alliance Global Partners analyst A. Grey now forecasts that the company will post earnings per share of ($0.02) for the quarter, up from their previous estimate of ($0.03). The consensus estimate for Cresco Labs’ current full-year earnings is ($0.20) per share. Alliance Global Partners also issued estimates for Cresco Labs’ Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.09) EPS and FY2026 earnings at ($0.08) EPS.

A number of other brokerages have also commented on CRLBF. Atb Cap Markets lowered Cresco Labs from a “strong-buy” rating to a “hold” rating in a report on Monday, December 9th. Cormark raised shares of Cresco Labs from a “hold” rating to a “moderate buy” rating in a report on Monday. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Cresco Labs presently has an average rating of “Buy” and an average price target of $3.00.

Cresco Labs Trading Down 4.0 %

Cresco Labs stock opened at $0.71 on Monday. The business’s 50-day simple moving average is $0.88 and its 200-day simple moving average is $1.19. Cresco Labs has a 52 week low of $0.70 and a 52 week high of $2.60. The firm has a market capitalization of $344.14 million, a PE ratio of -3.53 and a beta of 1.79. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.39 and a current ratio of 1.97.

Cresco Labs (OTCMKTS:CRLBF) last issued its quarterly earnings data on Friday, March 14th. The company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01). Cresco Labs had a negative return on equity of 16.52% and a negative net margin of 9.15%. The business had revenue of $176.00 million for the quarter, compared to analyst estimates of $172.10 million.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.